Search

Objective: To discuss the difference in the quality of life and nutritional status in patients with severe stable chronic obstructive pulmonary disease (COPD) with different phenotypes. Methods: 79 stable patients with severe COPD (grade Ⅲ) from January 2017 to June 2018 in Shidong Hospital of Yangpu District in Shanghai were selected and divided into chronic bronchitis (CB) group (n=48) and non CB group (n=31) according to their clinical phenotypes. The values of pulmonary function, MNA (mini nutritional assessment), CAT(COPD Assessment Test), mMRC (Modified Medical Research Council Dyspnea), ADL (Activity of Daily Living Scale), grip strength and 6-minute walking distance of all patients were collected and analyzed. Results: The values of MNA, CAT, ADL, mMRC in non CB group were better than those in CB group (all P<0.05). And 6-minute walking distance of non CB group is better(t=2.256, P<0.05). In CB group, the value of MNA was positively correlated with FEV1 / predicted value, FVC, 6-minute walking distance, ADL and grip strength (r=0.441, 0.379, 0.442, 0.511, 0.316, all P<0.05), but negatively correlated with CAT and mMRC (r=-0.385, -0.460, all P<0.05). In non CB group, the value of MNA was only negatively correlated with CAT (r=-0.376, P<0.05), but was not correlated with FEV1, FVC, 6-minute walking distance, mMRC and ADL (P>0.05). Conclusion: The quality of life and nutritional status of patients in non CB group with severe stable COPD are better than those in CB group. It suggests that COPD patients with CB phenotype may need more nutritional support to improve their quality of life. [ABSTRACT FROM AUTHOR]

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To explore the role of fibroblast growth factor 23 (FGF23) in patients with end-stage renal disease. Methods: 58 cases with end stage renal disease who were treated in our hospital from February 2013 to May 2015 were selected and according to the iPTH values, the patients were divided into two groups: iPTH > 300 pg / mL as the observation group. 150 pg inL< iPHT2 300 pg inL as the control group, with 29 patients in each group. Then the calcium, phosphorus, albumin, blood lipids, and levels of FGF23. iPTH. 1.25 （OH)2D3 in the two groups were observed and compared. Results: The levels of FGF23 and iPTH in the observation group were significantly higher than those of the control group, and the differences were statistically significant (P<0.05). Compared with the control group, the blood urea nitrogen, creatinine and dialysis in the observation group significantly decreased, and the difference was statistically significant (P< 0.01): The FGF23 and iPTH decreased in the two groups, and the difference was statistically significant (P < 0.01). 1.25 （OH)2D3 and serum albumin level were the independent influencing factors of FGF23 Log. Conclusion: FGF23 plays a role in the pathogenesis of secondary parathyroid function in patients with end-stage renal disease. [ABSTRACT FROM AUTHOR]

Objective: To study the clinical value of semi-permanent internal jugular vein catheter in hemodialysis. Method: A total of 84 patients, who were admitted to Affiliated Hospital of Yan'an University from October 2013 to October 2014, were selected and divided into study group(n=42) and control group(n=42). The study group was given semi-permanent internal jugular vein catheter, and the control group, artificial vascular fistula. The clinical data of two groups were compared and analysed. Results: The catheter indwelling time (23.2 ± 0.8 months) of study group was significantly longer than that（12.8 ± 0.8 months) of control group, the difference was statistically significant (P<0.05). Poor catheter function and infection of the study group were significantly less than those of the control group, the difference was statistically significant (P<0.05). There was no significant adverse reactions in the study group, while there were 2 cases of difficult hemostasis and 6 cases of thrombosis in the control group. Conclusion: Semi-permanent internal jugular vein catheter has the advantages of convenient and less adverse reactions, which can be applied to the need of hemodialysis patients. [ABSTRACT FROM AUTHOR]